The clinical and immunological safety of inactivated immunologic adjuvant influenza subunit vaccine for pregnant women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the clinical and immunological safety of influenza vaccines in pregnant women, as well as pregnancy outcome. Material and methods. A blind placebo-controlled study was conducted in 137 women in the second and third trimesters of physiological pregnancy who had received single vaccination against influenza in the season of 2010-2011. Group 1 comprised 43 women vaccinated with the Russian monovalent subunit adjuvant vaccine monogrippol plus (A/H1N1v strain 5 μg, Polyoxidonium 500 μg); Group 2 included 50 pregnant women vaccinated with the trivalent subunit adjuvant vaccine grippol plus (5 μg of each strain: A/H1N1v, H3N2, and B, 500 μg of polyoxydonium (Petrovax, Russia); Group 3 consisted of 44 pregnant women vaccinated with the commercial triple subunit vaccine agrippal containing 15 μg in each of the above 3 strains of antigens (Novartis Vaccines and Diagnostics, Italy). A control group included 41 pregnant women who had placebo (phosphate salt buffer). Clinical, biochemical, immunological, and statistical studies were used. Results. Assessment of the clinical course of the postvaccinal period showed that the asymptomatic course was recorded in 58.1% of the pregnant women in Group 1, 60.0% in Group 2, 54.5% in Group 3, and 60.9% in Group 4 (p > 0.05), which were not different from Group 5 (30 (61.3%) vaccinated nonpregnant women). Local systemic reactions were slightly marked, comparable in all the groups, and unaccompanied by deterioration in the status of pregnant women. On days 7 and 30, there were no pronounced changes in the results of biochemical blood tests in each examined group (p > 0.05), lipidograms, hormonal profile, and serum immunoglobulins. There was a difference in the short-term increase in INF-γ in the pregnant women in the second trimester of pregnancy in the use of immunologic adjuvant subunit vaccines, which was presumably associated with the involvement of Th1-mediated mechanisms in a postvaccinal immune response. As for an adjuvant-free analogue, there was an elevation of IL-4 (a sign of Th2-dependent activation), especially in the vaccinated in the third trimester of pregnancy. All the found shifts in the values recorded in different groups of the vaccinated persons were within the allowable limits. Pregnancy resulted in physiological birth in 85.4-90.7% of cases in all the groups. Conclusion. The injection of the Russian immunologic adjuvant influenza vaccine is immunologically safe and does not affect the course of pregnancy.

Full Text

Restricted Access

About the authors

Mikhail Petrovich Kostinov

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: vacdnums@gmail.com
MD, Professor, Honored Worker of Science, Head of laboratory vaccinal and immunotherapy of allergic diseases

Aleksandr Petrovich Cherdantsev

Ulyanovsk State University, Ministry of Health of Russia

Email: a_cherdantsev@rambler.ru
MD, Associate Professor of Pediatrics

References

  1. Hulka J.F. Effectiveness of polyvalent influenza vaccine in pregnancy. Report of a controlled study during an outbreak of Asian influenza. Obstet. Gynecol. 1964; 23: 830-7.
  2. Hall C.B., Lee H., Alexson C., Meagher M.P., Manning J.A. Trial of bivalent influenza A vaccine in high-risk infants. J. Infect. Dis. 1977; 136(Suppl.): S648-51.
  3. Heinonen O.P., Shapiro S., Monson R.R., Hartz S.C., Rosenberg L., Slone D. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int. J. Epidemiol. 1973; 2(3): 229-35.
  4. France E.K., Smith-Ray R., McClure D., Hambidge S., Xu S., Yamasaki K. et al. Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. Arch. Pediatr. Adolesc. Med. 2006; 160(12): 1277-83.
  5. Munoz F.M., Greisinger A.J., Wehmanen O.A., Mouzoon M.E., Hoyle J.C., Smith F.A., Glezen W.P. Safety of influenza vaccination during pregnancy. Am. J. Obstet. Gynecol. 2005; 192(4): 1098-106.
  6. Girard M.P., Katz J.M., Pervikov Y., Hombach J., Tam J.S. Report of the 7th meeting on evaluation of pandemic influenza vaccines in clinical trials. World Health Organization, Geneva, 17-18 February 2011. Vaccine. 2011; 29(44): 7579-86.
  7. Folkenberg M., Callréus T., Svanström H., Valentiner-Branth P., Hviid A. Spontaneous reporting of adverse events following immunisation against pan demic influenza in Denmark November 2009-March 2010. Vaccine. 2011; 29(6): 1180-4.
  8. Lim S.H., Lee J.H., Kim B.C., Jung S.U., Park Y.B., Lee C.S. Adverse reaction of influenza A(H1N1) 2009 virus vaccination in pregnant women and its effect on newborns. Vaccine. 2010; 28(47):7455-6.
  9. Parretta E., Ianniello B., Ferrazin F., Rossi F., Capuano A. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine. 2011; 29(20): 3708-13.
  10. Tavares F., Nazareth I., Monegal J.S., Kolte I., Verstraeten T., Bauchau V. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. Vaccine. 2011; 29(37): 6358-65.
  11. Tsai T., Kyaw M.H., Novicki D., Nacci P., Rai S., Clemens R. Exposure to MF59-adjvanted influenza vaccines during pregnancy - a retrospective analysis. Vaccine. 2010; 28(7):1877-80.
  12. Национальный календарь профилактических прививок. Приложение № 1 к приказу Министерства здравоохранения Российской Федерации от 21 марта 2014 года № 125н. [National Calendar of preventive vaccinations. Appendix № 1 to the order of the Ministry of Health of the Russian Federation dated 21 March 2014 № 125n. (in Russian)]
  13. Зверев В.В., Костиков М.П., Черданцев А.П., Кусельман А.И., Киселев О.И., Ерофеева М.К., Краснопольский В.И., Новикова С.В., Серова О.Ф., Брико Н.И., Чучалин А.Г. Вакцинация беременных против гриппа. Федеральные клинические рекомендации. М.: Ремедиум; 2015. 42с. [Zverev V.V., Kostin M.P., Cherdantsev A.P., Kuselman A.I., Kiselev O.I., Erofeeva M.K., Krasnopolskiy V.I., Novikova S.V., Serova O.F., Briko N.I., Chuchalin A.G. Vaccinating pregnant women against influenza. Federal clinical guidelines. Moscow: Remedium; 2015. 42c. (in Russian)]

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies